actbiotechАктуальная биотехнологияTopical biotechnology2304-4691ВГУИТ10.20914/2304-4691-2019-3-341-342actbiotech-4275Research ArticleСтатьиМОНОКЛОНАЛЬНЫЕ АНТИТЕЛА ДЛЯ ДЕТЕКЦИИ СА-125 И MISRII - ПОВЕРХНОСТНЫХ МАРКЕРОВ АДЕНОКАРЦИНОМЫ ЯИЧНИКОВРакА. Я.noemail@neicon.ruТрофимовА. В.noemail@neicon.ruИщенкоА. М.noemail@neicon.ruГосударственный научно-исследовательский институт особо чистых биопрепаратовRussian Federation20191809201903341342Copyright © Рак А.Я., Трофимов А.В., Ищенко А.М., 20192019Рак А.Я., Трофимов А.В., Ищенко А.М.Рак А.Я., Трофимов А.В., Ищенко А.М.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.actbio-vsuet.ru/jour/article/view/4275ReferencesSiegel R.L., Miller K.D., Jemal A. Cancer statistics, 2019 //CA: a cancer journal for clinicians. - 2019. - Vol. 69. - №. 1. - P. 7-34.Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2019 //CA: a cancer journal for clinicians. - 2019. - Vol. 69. - №. 1. - P. 7-34.Barnholtz-Sloan J.S. et al. Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades //American journal of obstetrics and gynecology. - 2003. - Vol. 189. - №. 4. - P. 1120-1127.Barnholtz-Sloan J.S. et al. Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades //American journal of obstetrics and gynecology. - 2003. - Vol. 189. - №. 4. - P. 1120-1127.Van der Burg M.E., Lammes F.B., Verweij J. CA 125 in ovarian cancer //The Netherlands journal of medicine. - 1992. - Vol. 40. - №. 1-2. - P. 36-51.Van der Burg M.E., Lammes F.B., Verweij J. CA 125 in ovarian cancer //The Netherlands journal of medicine. - 1992. - Vol. 40. - №. 1-2. - P. 36-51.Bakkum-Gamez J.N. et al. Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers //Gynecologic oncology. - 2008. - Vol. 108. - №. 1. - P. 141-148.Bakkum-Gamez J.N. et al. Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers //Gynecologic oncology. - 2008. - Vol. 108. - №. 1. - P. 141-148.Estupina P. et al. The anti-tumor efficacy of 3С23К, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells // Oncotarget. - 2017. - Vol. 8. - №. 23. - P. 37061-37079.Estupina P. et al. The anti-tumor efficacy of 3С23К, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells // Oncotarget. - 2017. - Vol. 8. - №. 23. - P. 37061-37079.
The authors declare that there are no conflicts of interest present.